State-of-the-Art ReviewThrombotic Risk and Antithrombotic Strategies After Transcatheter Mitral Valve Replacement
Under an Elsevier user license
open archive
Central Illustration
Key Words
antithrombotic therapy
anticoagulation
thrombosis
THV
TMVR
Abbreviations and Acronyms
CT
computed tomography
INR
international normalized ratio
MR
mitral regurgitation
MV
mitral valve
TAVR
transcatheter aortic valve replacement
THV
transcatheter heart valve
TMVR
transcatheter mitral valve replacement
ViMAC
valve-in-mitral annular calcification
ViR
valve-in-ring
ViV
valve-in-valve
VKA
vitamin K antagonist
Cited by (0)
Dr. Latib has served on the advisory board for Medtronic, Abbott Vascular, and Cardiovalve. Dr. Weisz has served on the medical advisory board for Corindus, Eco Fusion, Filterlex, Medivizor, and Trisol; and has received institutional research grants from Abbott Vascular, Corindus, Cardiovascular Systems, Inc., CSL Behring, RenalGuard, and Svelte. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
© 2019 by the American College of Cardiology Foundation. Published by Elsevier.